JPRN-UMIN000018594
Completed
Phase 1
Clinical Study of Therapeutic Angiogenesis Using Hypoxic Preconditioned Peripheral Blood Mononuclear Cells - Clinical Study of Therapeutic Angiogenesis Using Hypoxic preconditioned PBMNCs
Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science0 sites7 target enrollmentAugust 7, 2015
ConditionsPeripheral arterial occlusive disease
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Peripheral arterial occlusive disease
- Sponsor
- Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science
- Enrollment
- 7
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients suffering from bacterial infections such as treponema palladium, chlamydia, gonorrhea and tuberculosis. 2\. Patients suffering from infections such as hepatitis B and C viruses, human immunodeficiency virus, human T lymphotropic virus type 1 and parvovirus B19\. 3\. Patients with sepsis or suspected with. 4\. Patients with malignant neoplasm or history of malignant neoplasm treatmented within five years. 5\. Patients with serious endocrine disorders such as uncontrolled thyroid disfunction. 6\. Patients with blood disorders except for chronic kidney disease. 7\. Patients with liver disease with Child\-Pugh classification B or more. 8\. Patients with transmissible spongiform encephalopathy or suspected with. 9\. Patients with dementia with a a revised version Hasegawa dementia scale score smaller than 4\. 10\. Patient determined to be ineligible for this clinical study by research attending physician.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Multicenter trial of therapeutic angiogenesis in patients with intractable vasculitisJPRN-UMIN000000939Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine40
Recruiting
Phase 1
ICS-001-1CLTI (ASO or Buerger's disease) with refractory ulcer refractory to existing therapyJPRN-jRCT2052230115Kenichi Yamahara6
Recruiting
Not Applicable
A new treatment for skin ulcers associated with systemic sclerosis using the ability of own bone marrow cells to regenerate blood vesselsSystemic sclerosisSystemic sclerosis, Vasculopathy, Skin ulcer, Raynaud's phenomenonJPRN-jRCTb032210204Yoshimi Ryusuke12
Active, not recruiting
Not Applicable
Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within theSwedish Association of Breast Oncologists SABO-2010-01Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-022065-10-SESahlgrenska University Hospital
Completed
Phase 1
Clinical trial of new therapeutic angiogenesis for peripheral artery diseaseArteriosclerosis obliterans Buerger's diseaseJPRN-UMIN000005277Kyoto Prefectural University of Medicine10